Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Retained Earnings (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Retained Earnings for 15 consecutive years, with -$342.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 7.69% to -$342.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$342.2 million, a 7.69% decrease, with the full-year FY2025 number at -$333.5 million, down 4.24% from a year prior.
  • Retained Earnings was -$342.2 million for Q4 2025 at Aytu Biopharma, down from -$331.6 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$178.3 million in Q2 2021 to a low of -$342.2 million in Q4 2025.
  • A 5-year average of -$292.9 million and a median of -$312.2 million in 2023 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: crashed 65.83% in 2021, then grew 0.52% in 2025.
  • Aytu Biopharma's Retained Earnings stood at -$217.7 million in 2021, then crashed by 35.27% to -$294.5 million in 2022, then fell by 6.11% to -$312.5 million in 2023, then dropped by 1.68% to -$317.7 million in 2024, then decreased by 7.69% to -$342.2 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Retained Earnings are -$342.2 million (Q4 2025), -$331.6 million (Q3 2025), and -$333.5 million (Q2 2025).